

# 1 **Supplementary materials**

## 2 **Contents:**

3 Supplementary file 1: Search strategy for the literature review

4 Supplementary File 2: Quality scoring criteria

5 Supplementary File 3: Set of predictors used for the Stage 2 extrapolation

6 Supplementary File 4: RSV-associated hospitalisation rates per 1,000 population per age group

7 per year calculated by using the multiple imputation approach plus the first set of indicators

8 Supplementary File 5: RSV-associated hospitalisation rates per 1,000 population per age group

9 per year calculated by using the multiple imputation approach plus the second set of indicators

10 Supplementary File 6: RSV-associated hospitalisation rates per 1,000 population per age group

11 per year calculated by using the nearest neighbor matching approach plus the first set of

12 indicators

13 Supplementary File 7: RSV-associated hospitalisation rates per 1,000 population per age group

14 per year calculated by using the nearest neighbor matching approach plus the second set of

15 indicators

16 Supplementary File 8: RSV-associated hospitalisations per age group per year calculated by

17 using the multiple imputation approach plus the first set of indicators

18 Supplementary File 9: RSV-associated hospitalisations per age group per year calculated by

19 using the multiple imputation approach plus the second set of indicators

20 Supplementary File 10: RSV-associated hospitalisations per age group per year calculated by

21 using the nearest neighbor matching approach plus the first set of indicators

22 Supplementary File 11: RSV-associated hospitalisations per age group per year calculated by

23 using the nearest neighbor matching approach plus the second set of indicators

24 Supplementary File 12: Description of individual studies included in the analysis\*

25 Supplementary File 13: PRISMA 2020 Checklist



## Supplementary file 1: Search strategy for the literature review

### Medline

1. exp Respiratory Syncytial Virus Infections/ or exp Respiratory Syncytial Viruses/ or RSV.mp. or exp Respiratory Syncytial Virus, Human/
2. respiratory syncytial virus\*.mp.
3. exp Pneumonia/ or exp Pneumonia, Viral/ or pneumonia.mp.
4. bronchiolitis.mp. or exp Bronchiolitis/ or exp Bronchiolitis, Viral/
5. exp Respiratory Tract Infections/ or respiratory infection\*.mp.
6. respiratory disease\*.mp. or exp Respiratory Tract Diseases/
7. exp Hospital Mortality/ or exp Mortality/ or mortality.mp.
8. exp Death/ or death\*.mp. or exp "Cause of Death"/
9. exp Hospitalization/ or hospitalization\*.mp.
10. burden.mp.
11. exp Epidemiology/ or epidemiology.mp.
12. exp Models, Statistical/ or statistical model\*.mp.
13. model\*.mp.
14. estimat\*.mp.
15. modelling estimate\*.mp.
16. 1 or 2
17. 3 or 4 or 5 or 6
18. 7 or 8 or 9 or 10 or 11
19. 12 or 13 or 14 or 15
20. 16 and 17 and 18 and 19
21. limit 20 to (da="1995 - 20200127" and (female or humans or male))

## Embase

1. exp Respiratory syncytial pneumovirus/ or RSV.mp. or exp respiratory syncytial virus infection/
2. respiratory syncytial virus\*.mp.
3. exp pneumonia/ or exp community acquired pneumonia/ or exp infectious pneumonia/ or pneumonia.mp. or exp virus pneumonia/
4. bronchiolitis.mp. or exp bronchiolitis/ or exp viral bronchiolitis/
5. exp respiratory tract infection/ or respiratory infection\*.mp.
6. exp respiratory tract disease/ or respiratory disease\*.mp.
7. exp hospital mortality/ or mortality.mp. or exp mortality/ or exp mortality rate/
8. exp death/ or death\*.mp. or exp "cause of death"/
9. exp hospitalization/ or hospitalization\*.mp.
10. burden.mp.
11. exp epidemiology/ or epidemiology.mp.
12. exp statistical model/ or statistical model\*.mp. or exp model/
13. model\*.mp.
14. estimat\*.mp.
15. modelling estimate\*.mp.
16. 1 or 2
17. 3 or 4 or 5 or 6
18. 7 or 8 or 9 or 10 or 11
19. 12 or 13 or 14 or 15
20. 16 and 17 and 18 and 19
21. limit 20 to (da="1995 - 20200127" and "humans only (removes records about animals)")

1 Supplementary File 2: Quality scoring criteria

Category	Questions	Scoring criteria
Study design	Q1. Whether cases were prospectively enrolled?	<ul style="list-style-type: none"> <li>• Yes – <b>1 point</b></li> <li>• No/unclear – 0 points</li> </ul>
Study subjects	Q2. Any subgroup(s) exclusion that may have affected estimates?	<ul style="list-style-type: none"> <li>• No – <b>1 point</b></li> <li>• Yes/unclear – 0 points (e.g., excluding neonates)</li> </ul>
Case definition	Q3. Whether common/standard definitions were used?	<ul style="list-style-type: none"> <li>• Yes – <b>1 point</b></li> <li>• No/unclear – 0 points</li> </ul>
Sampling strategy	Q4. What is the proportion of eligible ALRI cases that were tested for RSV?	<ul style="list-style-type: none"> <li>• <math>\geq 90\%</math> – <b>1 point</b></li> <li>• <math>&lt; 90\%</math> but a systematic sample of eligible cases were tested – <b>1 point</b></li> <li>• <math>&lt; 90\%</math>/unclear – 0 points</li> </ul>
Diagnostic test	Q5. Whether PCR was used for the confirmation of RSV infection*?	<ul style="list-style-type: none"> <li>• Yes – <b>1 point</b></li> <li>• No/unclear – 0 points</li> </ul>
Adjustment for healthcare utilisation	Q6. Whether healthcare utilisation was adjusted when calculating hospital admission rate?	<ul style="list-style-type: none"> <li>• Including all or main hospitals of the area; no need for adjustment – <b>1 point</b></li> <li>• Adjusting for the proportion of patients admitted in the study hospitals – <b>1 point</b></li> <li>• Not including all or main hospitals of the area and not adjusting for healthcare utilisation – 0 point</li> </ul>

3 Supplementary File 3: Set of predictors used for the Stage 2 extrapolation

4

5 Indicator set 1:

- 6 - % total population age 0-14
- 7 - % total population age 60 plus
- 8 - death rate in specific age group (first three age groups death rate 0 years)
- 9 - % primary and lower secondary education adult population
- 10 - household income
- 11 - % deprived adult population
- 12 - % working in high-tech jobs
- 13 - % manual working
- 14 - % unemployed age 20-64
- 15 - agricultural output

16

17 Indicator set 2:

- 18 - % total population age 0-14
- 19 - % total population age 60 plus
- 20 - death rate in specific age group (first three age groups deathrate 0 years)
- 21 - % primary and lower secondary education adult population
- 22 - household income
- 23 - curative hospital beds per 100000 population
- 24 - % health and social workers of total workers
- 25 - industrial crop
- 26 - fruits production
- 27 - youth unemployment

28 Sources:

29 - Population and death-rates come from the Human Mortality database. Available at

30 <https://www.mortality.org/> [Last accessed 01 March 2022].

31 - Eurostat. Available at: <https://ec.europa.eu/eurostat/data/database> [Last accessed 01

32 March 2022].

Supplementary File 4: RSV-associated hospitalisation rates per 1,000 population per age group per year calculated by using the multiple imputation approach plus the first set of indicators

Country	0-2 months (95%CI) <sup>a</sup>	3-5 months (95%CI) <sup>a</sup>	6-11 months (95%CI) <sup>a</sup>	12-35 months (95%CI) <sup>b</sup>	36-59 months (95%CI) <sup>b</sup>
EU28 <sup>c</sup>	69.7 (64.5-74.9)	39.8 (35.8-43.9)	17.5 (15.5-19.4)	5.3 (4.7-6)	1.1 (0.9-1.2)
Austria	62 (51.8-72.3)	36.5 (29.5-43.5)	12.2 (9.2-15.1)	5 (3.9-6)	1 (0.8-1.3)
Belgium	67.3 (57-77.5)	41.2 (34.2-48.2)	18.5 (15.5-21.4)	6.1 (5.1-7.2)	1.4 (1.1-1.7)
Bulgaria	89.2 (78.9-99.5)	65.9 (58.9-72.8)	27.7 (24.8-30.7)	9.3 (8.3-10.4)	1.4 (1.1-1.6)
Croatia	81.4 (71.1-91.7)	41.1 (34.1-48.1)	19.3 (16.3-22.2)	4.3 (3.3-5.4)	0.7 (0.5-1)
Cyprus	75.7 (65.4-86)	39.6 (32.6-46.5)	11.7 (8.8-14.6)	5.3 (4.2-6.3)	0.8 (0.6-1.1)
Czech Republic	69.5 (59.2-79.8)	44.4 (37.4-51.4)	18.9 (16-21.8)	7.3 (6.3-8.4)	1.3 (1-1.5)
Denmark	58.7 (48.4-69)	41.6 (34.6-48.6)	20.7 (17.8-23.6)	7.8 (6.7-8.8)	1.6 (1.4-1.9)
Estonia	68.6 (58.3-78.8)	31.6 (24.6-38.6)	12.8 (9.9-15.7)	4.8 (3.7-5.8)	1.1 (0.8-1.3)
Finland	78 (67.7-88.3)	44.1 (37.2-51.1)	16.5 (13.6-19.4)	5.3 (4.3-6.4)	0.8 (0.5-1)
France	100 (89.8-110.3)	50.4 (43.4-57.4)	27.1 (24.2-30)	3.5 (2.4-4.5)	0.8 (0.6-1.1)
Germany	61.7 (51.4-72)	43 (36-50)	15.8 (12.9-18.7)	4.8 (3.8-5.9)	0.8 (0.6-1.1)
Greece	93.9 (83.7-104.2)	50.8 (43.8-57.8)	21.3 (18.4-24.2)	5.2 (4.1-6.2)	0.8 (0.5-1)
Hungary	75.6 (65.4-85.9)	59 (52-66)	21.7 (18.8-24.6)	6.9 (5.8-7.9)	1.4 (1.1-1.6)
Ireland	57.8 (47.5-68.1)	54 (47-61)	26.9 (24-29.9)	9.1 (8.1-10.2)	1.7 (1.5-2)



Italy	67.7 (57.4-78)	36.3 (29.3-43.3)	18.6 (15.7-21.5)	4.6 (3.5-5.6)	0.9 (0.7-1.2)
Latvia	78.7 (68.5-89)	41.1 (34.1-48.1)	15.5 (12.6-18.4)	3.8 (2.8-4.9)	1 (0.8-1.3)
Lithuania	81.1 (70.8-91.4)	38.2 (31.2-45.2)	15.6 (12.7-18.5)	2.9 (1.8-3.9)	0.6 (0.4-0.9)
Luxembourg	59.9 (49.6-70.2)	30 (23-37)	7.6 (4.7-10.5)	5 (3.9-6)	1.1 (0.9-1.4)
Malta	53 (42.7-63.3)	28.7 (21.7-35.7)	18.3 (15.3-21.2)	6.6 (5.5-7.6)	1.8 (1.5-2.1)
Netherlands	46.5 (36.3-56.8)	19.7 (12.7-26.6)	7.4 (4.5-10.4)	1.6 (0.6-2.7)	1 (0.8-1.3)
Norway	53.3 (43-63.5)	35.2 (28.2-42.1)	14.9 (12-17.9)	6.9 (5.8-7.9)	0.4 (0.2-0.7)
Poland	64.1 (53.9-74.4)	28.8 (21.8-35.8)	13.5 (10.5-16.4)	3.9 (2.8-4.9)	0.6 (0.4-0.9)
Portugal	64.7 (54.4-74.9)	24.8 (17.8-31.8)	11.9 (9-14.8)	5 (3.9-6)	1.5 (1.2-1.7)
Romania	71.7 (61.4-82)	35.2 (28.2-42.2)	23.1 (20.2-26)	5.4 (4.3-6.4)	1 (0.7-1.2)
Slovakia	68.5 (58.2-78.8)	42.9 (35.9-49.8)	22.6 (19.7-25.6)	5.1 (4-6.1)	0.7 (0.5-1)
Slovenia	68.1 (57.9-78.4)	51.9 (44.9-58.9)	18.3 (15.3-21.2)	6.3 (5.3-7.4)	1.3 (1-1.6)
Spain	66.1 (55.9-76.4)	24.6 (17.7-31.6)	16.9 (14-19.8)	3 (1.9-4)	0.8 (0.5-1.1)
Sweden	69.4 (59.1-79.7)	35.3 (28.3-42.2)	14.6 (11.6-17.5)	4.7 (3.7-5.8)	1.3 (1-1.5)
United Kingdom	60.8 (44.3-77.2)	38.3 (25.6-51.1)	18.8 (12.7-24.8)	6.4 (4.3-8.4)	1.1 (0.7-1.6)

<sup>a</sup> RSV-associated hospitalisation rates in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisation rates in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 5: RSV-associated hospitalisation rates per 1,000 population per age group per year calculated by using the multiple imputation approach plus the second set of indicators

Country	0-2 months (95%CI) <sup>a</sup>	3-5 months (95%CI) <sup>a</sup>	6-11 months (95%CI) <sup>a</sup>	12-35 months (95%CI) <sup>b</sup>	36-59 months (95%CI) <sup>b</sup>
EU28 <sup>c</sup>	71.3 (65.9-76.6)	37.7 (34.8-40.7)	17.2 (15.8-18.6)	5.4 (4.8-5.9)	1.1 (1-1.2)
Austria	72 (64.4-79.6)	30.4 (25.8-35)	12.4 (10.2-14.7)	4.2 (3.2-5.1)	0.8 (0.6-1)
Belgium	79 (71.4-86.6)	39.4 (34.8-44)	15.1 (12.8-17.3)	4.3 (3.4-5.3)	1 (0.8-1.2)
Bulgaria	86.6 (79-94.2)	47.6 (43-52.2)	20.7 (18.4-22.9)	4.5 (3.6-5.5)	1 (0.8-1.2)
Croatia	82.1 (74.5-89.7)	46.1 (41.5-50.8)	18.4 (16.1-20.6)	6.3 (5.3-7.2)	1.2 (0.9-1.4)
Cyprus	84.2 (76.6-91.8)	43.1 (38.5-47.7)	17.5 (15.3-19.8)	7.1 (6.2-8.1)	1.1 (0.9-1.3)
Czech Republic	68.7 (61.1-76.3)	35.1 (30.5-39.7)	16.8 (14.5-19)	5.7 (4.8-6.7)	1.2 (1-1.4)
Denmark	57.5 (49.9-65.1)	40.7 (36.1-45.3)	20.4 (18.1-22.7)	7.7 (6.8-8.7)	1.6 (1.4-1.8)
Estonia	58.3 (50.7-65.9)	33.5 (28.9-38.1)	17.4 (15.2-19.7)	5.6 (4.6-6.5)	1 (0.8-1.2)
Finland	78.9 (71.3-86.5)	43.3 (38.7-47.9)	16.3 (14-18.5)	5.3 (4.4-6.3)	0.8 (0.6-1)
France	103.2 (95.6-110.8)	49.8 (45.2-54.4)	26.7 (24.5-29)	6 (5.1-7)	1.4 (1.2-1.6)
Germany	88.4 (80.8-96)	39.3 (34.7-43.9)	21.9 (19.6-24.1)	6.5 (5.5-7.4)	1.2 (0.9-1.4)
Greece	88.4 (80.8-96)	47.9 (43.3-52.5)	19.1 (16.8-21.3)	5.8 (4.9-6.8)	1.1 (0.9-1.3)
Hungary	73.5 (65.8-81.1)	36.7 (32.1-41.3)	18.4 (16.1-20.7)	5.3 (4.3-6.2)	1.1 (0.9-1.3)
Ireland	62.5 (54.8-70.1)	47.3 (42.7-51.9)	21.9 (19.6-24.1)	8.5 (7.6-9.5)	1.4 (1.2-1.6)

Italy	94.7 (87.1-102.3)	46.9 (42.2-51.5)	16.7 (14.5-19)	4.9 (3.9-5.9)	0.9 (0.7-1.1)
Latvia	60.8 (53.2-68.4)	38.3 (33.7-42.9)	18.4 (16.2-20.7)	5.4 (4.4-6.3)	1.2 (1-1.5)
Lithuania	64.6 (57-72.2)	31.7 (27.1-36.3)	14.2 (12-16.5)	3.5 (2.5-4.4)	1 (0.8-1.2)
Luxembourg	64.3 (56.7-71.9)	31.2 (26.6-35.8)	14.5 (12.2-16.7)	6.1 (5.2-7.1)	1 (0.8-1.2)
Malta	53.6 (46-61.2)	30.6 (26-35.3)	16.5 (14.2-18.7)	5.8 (4.9-6.8)	1.4 (1.1-1.6)
Netherlands	44.1 (36.5-51.7)	18.2 (13.6-22.8)	7.4 (5.1-9.6)	1.7 (0.8-2.7)	1.3 (1-1.5)
Norway	51.5 (43.9-59.1)	34.1 (29.5-38.7)	14.8 (12.5-17)	6.9 (5.9-7.8)	0.5 (0.3-0.7)
Poland	77.7 (70.1-85.3)	39.1 (34.5-43.7)	16.6 (14.4-18.9)	6.1 (5.1-7)	1.2 (0.9-1.4)
Portugal	63.5 (55.9-71.1)	21.2 (16.6-25.9)	14.9 (12.6-17.1)	4.1 (3.2-5.1)	1.4 (1.2-1.6)
Romania	66.1 (58.5-73.7)	44.3 (39.7-48.9)	22.3 (20-24.5)	4.3 (3.4-5.3)	1.1 (0.9-1.3)
Slovakia	80.8 (73.2-88.5)	43.6 (39-48.2)	15 (12.8-17.3)	4.8 (3.8-5.7)	0.8 (0.6-1)
Slovenia	70.5 (62.9-78.1)	31.4 (26.8-36)	14.1 (11.9-16.4)	5.3 (4.4-6.3)	1.1 (0.9-1.3)
Spain	64.3 (56.7-71.9)	30.8 (26.1-35.4)	14.6 (12.4-16.9)	3 (2.1-4)	0.8 (0.6-1.1)
Sweden	55.3 (47.7-62.9)	35 (30.4-39.6)	19.4 (17.1-21.6)	5.6 (4.6-6.6)	1.4 (1.2-1.6)
United Kingdom	67.5 (51-84)	42.1 (32.9-51.4)	20.1 (15.7-24.5)	5.9 (4.1-7.6)	1.4 (1.1-1.7)

<sup>a</sup> RSV-associated hospitalisation rates in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisation rates in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 6: RSV-associated hospitalisation rates per 1,000 population per age group per year calculated by using the nearest neighbor matching approach plus the first set of indicators

Country	0-2 months (95%CI) <sup>a</sup>	3-5 months (95%CI) <sup>a</sup>	6-11 months (95%CI) <sup>a</sup>	12-35 months (95%CI) <sup>b</sup>	36-59 months (95%CI) <sup>b</sup>
EU28 <sup>c</sup>	71.9 (67.4-76.4)	38.9 (36.6-41.2)	17.4 (16.1-18.7)	5 (4.5-5.5)	1 (0.9-1.1)
Austria	61.7 (51.5-71.9)	34 (29.2-38.9)	15.5 (12.6-18.4)	5.4 (4.3-6.5)	0.9 (0.7-1.1)
Belgium	61.2 (51-71.4)	32.8 (28-37.7)	14.8 (11.9-17.7)	5.1 (4-6.1)	1.2 (1-1.4)
Bulgaria	73.1 (62.9-83.2)	39.8 (34.9-44.6)	16.9 (14-19.8)	4.5 (3.5-5.6)	0.9 (0.7-1.1)
Croatia	78.3 (68.1-88.4)	42.5 (37.6-47.3)	19.3 (16.4-22.3)	4.9 (3.8-6)	0.9 (0.7-1.1)
Cyprus	77.1 (66.9-87.3)	41.5 (36.7-46.3)	18.7 (15.8-21.6)	5.4 (4.3-6.5)	0.9 (0.7-1.1)
Czech Republic	79.3 (69.1-89.4)	42.1 (37.2-46.9)	18 (15.1-20.9)	5.6 (4.5-6.6)	1.1 (0.9-1.3)
Denmark	59.2 (48.7-69.6)	40.1 (35.1-45.1)	19.9 (16.9-22.9)	7.4 (6.3-8.4)	1.6 (1.4-1.8)
Estonia	76.3 (65.8-86.8)	42.3 (37.3-47.3)	19.6 (16.6-22.6)	5.9 (4.8-6.9)	1.2 (1-1.4)
Finland	76.3 (65.9-86.8)	42.4 (37.4-47.3)	16.6 (13.6-19.6)	5.3 (4.3-6.4)	0.8 (0.6-1)
France	92.7 (82.5-102.9)	46.8 (42-51.7)	24.4 (21.4-27.3)	5.9 (4.8-7)	1.1 (0.9-1.3)
Germany	69.1 (58.9-79.3)	36.4 (31.6-41.2)	16 (13-18.9)	5.3 (4.3-6.4)	0.9 (0.7-1.1)
Greece	71.8 (61.6-81.9)	37.5 (32.7-42.3)	16.4 (13.5-19.3)	3.7 (2.6-4.8)	0.9 (0.7-1.1)
Hungary	71.6 (61.4-81.7)	39.9 (35.1-44.8)	18.2 (15.3-21.1)	5.2 (4.1-6.2)	1.1 (0.9-1.3)
Ireland	78.7 (68.5-88.8)	43.1 (38.3-48)	20.3 (17.4-23.2)	5.5 (4.4-6.6)	1 (0.8-1.2)

Italy	81.7 (71.6-91.9)	41.6 (36.8-46.5)	17.9 (14.9-20.8)	4.2 (3.1-5.3)	0.9 (0.7-1.1)
Latvia	80.3 (70.2-90.5)	43.1 (38.3-48)	19.5 (16.6-22.4)	5 (3.9-6)	1 (0.8-1.2)
Lithuania	74.4 (64.3-84.6)	41.8 (37-46.7)	18.1 (15.2-21)	5.1 (4.1-6.2)	1 (0.8-1.2)
Luxembourg	64 (53.8-74.2)	34 (29.2-38.9)	14.6 (11.6-17.5)	4.7 (3.6-5.8)	0.8 (0.6-1)
Malta	76.3 (65.8-86.7)	40.7 (35.8-45.7)	18.1 (15.1-21.1)	4.8 (3.7-6)	1.1 (0.8-1.3)
Netherlands	48.3 (37.8-58.8)	20.8 (15.8-25.8)	9.5 (6.5-12.4)	2.3 (1.3-3.4)	1.2 (1-1.4)
Norway	56.9 (46.3-67.6)	35.4 (30.4-40.3)	16 (13-19.1)	6.6 (5.5-7.7)	0.6 (0.4-0.8)
Poland	70 (59.9-80.2)	37.9 (33.1-42.7)	16 (13.1-18.9)	4.4 (3.3-5.5)	1 (0.8-1.2)
Portugal	77.4 (67.2-87.5)	41.1 (36.2-45.9)	17.4 (14.5-20.3)	4.8 (3.7-5.8)	1 (0.8-1.2)
Romania	66.8 (56.7-77)	34.4 (29.6-39.3)	14.6 (11.7-17.5)	3.8 (2.7-4.9)	1.1 (0.8-1.3)
Slovakia	75.2 (65.3-85.1)	41.4 (36.7-46.1)	18.7 (15.9-21.6)	5.2 (4.1-6.3)	0.9 (0.7-1.1)
Slovenia	79 (68.9-89.2)	43 (38.2-47.9)	18.4 (15.5-21.3)	5.3 (4.2-6.3)	1 (0.8-1.2)
Spain	74.7 (64.5-84.8)	36.9 (32.1-41.7)	17.2 (14.3-20.1)	3.2 (2.2-4.3)	0.9 (0.7-1.1)
Sweden	62.5 (52-72.9)	35.8 (30.8-40.8)	16.8 (13.8-19.8)	5.8 (4.7-6.9)	1.2 (1-1.4)
United Kingdom	62.3 (47.9-76.7)	36.7 (29.6-43.9)	17.5 (13.5-21.5)	6.3 (4.8-7.8)	1.5 (1.2-1.8)

<sup>a</sup> RSV-associated hospitalisation rates in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisation rates in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 7: RSV-associated hospitalisation rates per 1,000 population per age group per year calculated by using the nearest neighbor matching approach plus the second set of indicators

<b>Country</b>	<b>0-2 months (95%CI)<sup>a</sup></b>	<b>3-5 months (95%CI)<sup>a</sup></b>	<b>6-11 months (95%CI)<sup>a</sup></b>	<b>12-35 months (95%CI)<sup>b</sup></b>	<b>36-59 months (95%CI)<sup>b</sup></b>
EU28 <sup>c</sup>	73.5 (68.7-78.4)	39.3 (36.8-41.8)	18.3 (16.9-19.8)	4.1 (3.7-4.6)	0.9 (0.8-1)
Austria	64.3 (53.2-75.4)	31.5 (26.4-36.7)	14.1 (10.9-17.2)	3.5 (2.4-4.5)	0.8 (0.7-1)
Belgium	66.9 (55.8-78)	31.9 (26.7-37)	15.2 (12.1-18.4)	3.8 (2.8-4.9)	1.1 (0.9-1.2)
Bulgaria	78.2 (67.1-89.3)	42.5 (37.3-47.6)	19.6 (16.5-22.8)	3.8 (2.7-4.8)	0.8 (0.6-1)
Croatia	76 (64.9-87.1)	40.6 (35.4-45.8)	19.2 (16-22.3)	3.7 (2.6-4.8)	0.8 (0.6-1)
Cyprus	76.5 (65.4-87.6)	40.8 (35.7-46)	18.7 (15.6-21.9)	4.2 (3.2-5.3)	0.8 (0.6-1)
Czech Republic	78.1 (67-89.2)	42.5 (37.3-47.7)	20 (16.9-23.1)	4.1 (3-5.2)	0.9 (0.7-1.1)
Denmark	61.3 (50.2-72.4)	40.5 (35.4-45.7)	20.4 (17.3-23.6)	7 (5.9-8.1)	1.5 (1.3-1.7)
Estonia	76.2 (65.1-87.3)	41.7 (36.5-46.9)	19.1 (16-22.3)	4.2 (3.1-5.2)	0.9 (0.7-1.1)
Finland	78 (66.9-89.1)	42.8 (37.6-48)	17 (13.9-20.2)	5 (3.9-6)	0.8 (0.6-0.9)
France	97.1 (86-108.2)	48.4 (43.2-53.5)	25.7 (22.5-28.8)	4.6 (3.5-5.7)	1 (0.8-1.2)
Germany	70.7 (59.6-81.8)	35.6 (30.4-40.7)	16.1 (13-19.3)	4.3 (3.2-5.3)	0.9 (0.8-1.1)
Greece	76.3 (65.3-87.4)	40.8 (35.7-46)	19.5 (16.3-22.6)	3.1 (2-4.2)	0.8 (0.6-1)
Hungary	80.5 (69.4-91.6)	43.2 (38.1-48.4)	20.8 (17.6-23.9)	4.3 (3.2-5.4)	0.9 (0.7-1)
Ireland	81.5 (70.4-92.6)	43.6 (38.5-48.8)	21.3 (18.2-24.5)	5.1 (4-6.1)	0.9 (0.7-1.1)

Italy	79.4 (68.3-90.5)	42 (36.9-47.2)	19.4 (16.2-22.5)	3.4 (2.4-4.5)	1 (0.8-1.2)
Latvia	80 (68.9-91.1)	42.7 (37.6-47.9)	20.2 (17.1-23.3)	4.5 (3.4-5.5)	0.9 (0.7-1.1)
Lithuania	74.4 (63.3-85.5)	42.2 (37-47.3)	19.9 (16.8-23)	4.4 (3.4-5.5)	0.9 (0.8-1.1)
Luxembourg	65.8 (54.7-76.9)	35.2 (30-40.4)	15.8 (12.7-19)	4.2 (3.2-5.3)	0.8 (0.6-0.9)
Malta	76.2 (64.7-87.6)	40.8 (35.4-46.2)	18.7 (15.5-22)	4.5 (3.4-5.6)	0.9 (0.7-1.1)
Netherlands	50.8 (39.7-61.9)	21.1 (15.9-26.3)	9.7 (6.5-12.8)	1.8 (0.8-2.9)	0.9 (0.7-1.1)
Norway	56.8 (44.8-68.8)	34.7 (29.2-40.2)	15.7 (12.3-19.1)	6.2 (5.1-7.3)	0.5 (0.3-0.7)
Poland	73.6 (62.5-84.7)	40.2 (35.1-45.4)	18.9 (15.8-22.1)	3.9 (2.8-5)	0.8 (0.6-1)
Portugal	75.2 (64.1-86.3)	39.5 (34.3-44.6)	16.8 (13.7-19.9)	4 (2.9-5.1)	0.8 (0.7-1)
Romania	70.5 (59.4-81.5)	36.7 (31.6-41.9)	17.6 (14.4-20.7)	3 (1.9-4.1)	0.8 (0.7-1)
Slovakia	73.6 (62.5-84.7)	40.2 (35.1-45.4)	18.9 (15.8-22.1)	3.8 (2.8-4.9)	0.9 (0.7-1.1)
Slovenia	84 (72.9-95.1)	44 (38.9-49.2)	19.5 (16.4-22.7)	3.8 (2.8-4.9)	0.8 (0.7-1)
Spain	72.5 (61.4-83.6)	38 (32.8-43.1)	18.4 (15.2-21.5)	3 (1.9-4)	0.8 (0.6-1)
Sweden	64.7 (53.6-75.8)	36 (30.9-41.2)	16.9 (13.8-20)	5.1 (4-6.2)	0.9 (0.8-1.1)
United Kingdom	63.2 (48-78.4)	38.5 (30.8-46.1)	19.2 (14.8-23.6)	6 (4.5-7.6)	1.2 (1-1.5)

<sup>a</sup> RSV-associated hospitalisation rates in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisation rates in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 8: RSV-associated hospitalisations per age group per year calculated by using the multiple imputation approach plus the first set of indicators

<b>Country</b>	<b>0-2 months (95%CI)<sup>a</sup></b>	<b>3-5 months (95%CI)<sup>a</sup></b>	<b>6-11 months (95%CI)<sup>a</sup></b>	<b>12-35 months (95%CI)<sup>b</sup></b>	<b>36-59 months (95%CI)<sup>b</sup></b>
EU28 <sup>c</sup>	87,830 (81,265-94,395)	50,193 (45,044-55,341)	44,066 (39,141-48,990)	54,629 (47,788-61,470)	11,312 (9,834-12,789)
Austria	1,248 (1,041-1,455)	735 (594-876)	489 (372-607)	809 (638-979)	168 (127-210)
Belgium	2,099 (1,778-2,420)	1,286 (1,068-1,504)	1,152 (969-1,334)	1,562 (1,294-1,830)	370 (302-437)
Bulgaria	1,499 (1,327-1,672)	1,107 (989-1,224)	932 (834-1,030)	1,233 (1,094-1,372)	192 (157-227)
Croatia	802 (701-904)	405 (336-474)	380 (322-438)	354 (268-440)	63 (42-84)
Cyprus	175 (151-199)	91 (75-107)	54 (41-68)	101 (81-121)	16 (11-21)
Czech Republic	1,910 (1,628-2,193)	1,220 (1,028-1,412)	1,038 (877-1,199)	1,594 (1,365-1,823)	294 (236-353)
Denmark	839 (692-985)	594 (494-694)	591 (507-674)	901 (780-1,023)	203 (171-235)
Estonia	234 (199-269)	108 (84-132)	87 (67-107)	132 (103-161)	32 (24-40)
Finland	1,124 (976-1,273)	636 (536-737)	476 (392-560)	637 (512-762)	94 (62-125)
France	18,469 (16,571-20,367)	9,310 (8,020-10,600)	10,005 (8,925-11,085)	5,279 (3,692-6,866)	1,331 (932-1,730)
Germany	11,048 (9,206-12,889)	7,703 (6,451-8,955)	5,668 (4,620-6,716)	6,685 (5,225-8,145)	1,140 (790-1,491)
Greece	2,154 (1,918-2,390)	1,165 (1,005-1,325)	977 (843-1,111)	1,004 (801-1,207)	162 (107-216)
Hungary	1,756 (1,517-1,995)	1,370 (1,208-1,532)	1,006 (871-1,142)	1,246 (1,056-1,436)	246 (201-291)
Ireland	939 (772-1,106)	877 (763-990)	875 (780-970)	1,227 (1,086-1,369)	240 (204-276)



Italy	8,462 (7,177-9,747)	4,536 (3,663-5,410)	4,649 (3,918-5,381)	4,801 (3,705-5,898)	1,007 (729-1,285)
Latvia	427 (371-482)	223 (185-260)	168 (136-200)	156 (113-199)	39 (30-49)
Lithuania	615 (537-693)	290 (237-343)	237 (193-281)	175 (112-238)	39 (24-54)
Luxembourg	91 (75-106)	45 (35-56)	23 (14-32)	63 (50-77)	15 (11-18)
Malta	57 (46-68)	31 (23-38)	39 (33-45)	57 (48-66)	15 (13-18)
Netherlands	2,032 (1,583-2,481)	858 (553-1,163)	651 (395-906)	560 (195-926)	369 (276-462)
Norway	791 (638-943)	522 (418-626)	444 (357-531)	843 (714-971)	52 (20-84)
Poland	5,879 (4,937-6,822)	2,638 (1,997-3,279)	2,470 (1,934-3,007)	2,924 (2,128-3,720)	527 (321-733)
Portugal	1,330 (1,119-1,541)	511 (367-654)	489 (369-609)	858 (677-1,039)	284 (235-334)
Romania	3,440 (2,947-3,933)	1,690 (1,354-2,025)	2,216 (1,935-2,497)	2,002 (1,609-2,394)	390 (290-489)
Slovakia	951 (808-1,094)	595 (498-692)	629 (547-710)	571 (453-688)	87 (57-117)
Slovenia	360 (306-415)	274 (237-311)	193 (162-224)	275 (229-320)	59 (47-70)
Spain	7,052 (5,956-8,148)	2,628 (1,883-3,373)	3,600 (2,976-4,224)	2,593 (1,670-3,517)	762 (520-1,004)
Sweden	2,010 (1,712-2,308)	1,021 (819-1,224)	844 (675-1,014)	1,095 (851-1,339)	299 (239-359)
United Kingdom	11,813 (8,612-15,013)	7,449 (4,975-9,924)	7,293 (4,935-9,651)	10,229 (6,887-13,572)	1,882 (1,169-2,596)

<sup>a</sup> RSV-associated hospitalisations in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisations in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 9: RSV-associated hospitalisations per age group per year calculated by using the multiple imputation approach plus the second set of indicators

<b>Country</b>	<b>0-2 months (95%CI)<sup>a</sup></b>	<b>3-5 months (95%CI)<sup>a</sup></b>	<b>6-11 months (95%CI)<sup>a</sup></b>	<b>12-35 months (95%CI)<sup>b</sup></b>	<b>36-59 months (95%CI)<sup>b</sup></b>
EU28 <sup>c</sup>	89,748 (83,027-96,469)	47,534 (43,811-51,257)	43,388 (39,823-46,953)	54,995 (49,360-60,631)	11,722 (10,590-12,854)
Austria	1,448 (1,295-1,601)	611 (518-704)	499 (409-590)	678 (522-834)	129 (94-164)
Belgium	2,466 (2,229-2,703)	1,229 (1,085-1,373)	940 (799-1,080)	1,108 (862-1,353)	269 (212-326)
Bulgaria	1,456 (1,328-1,584)	800 (723-878)	695 (620-771)	599 (472-726)	141 (112-171)
Croatia	809 (734-884)	455 (409-500)	362 (318-407)	511 (432-589)	97 (79-115)
Cyprus	194 (177-212)	100 (89-110)	81 (71-91)	137 (118-155)	21 (17-25)
Czech Republic	1,888 (1,679-2,097)	965 (838-1,092)	921 (797-1,045)	1,247 (1,037-1,456)	279 (230-328)
Denmark	822 (713-930)	581 (516-647)	583 (518-647)	894 (782-1,005)	202 (175-229)
Estonia	199 (173-224)	114 (98-130)	119 (103-134)	154 (127-180)	31 (24-37)
Finland	1,137 (1,027-1,247)	625 (558-691)	470 (405-535)	637 (522-752)	99 (73-126)
France	19,059 (17,655-20,462)	9,191 (8,340-10,041)	9,868 (9,037-10,700)	9,136 (7,684-10,588)	2,217 (1,879-2,555)
Germany	15,826 (14,464-17,188)	7,036 (6,210-7,861)	7,841 (7,034-8,648)	8,968 (7,632-10,303)	1,597 (1,300-1,893)
Greece	2,028 (1,853-2,202)	1,098 (993-1,204)	875 (772-978)	1,125 (939-1,310)	240 (194-286)
Hungary	1,705 (1,529-1,882)	852 (745-959)	854 (750-959)	950 (777-1,124)	195 (156-233)
Ireland	1,014 (891-1,138)	769 (694-844)	710 (637-783)	1,148 (1,019-1,278)	194 (164-224)

Italy	11,838 (10,887-12,788)	5,856 (5,280-6,432)	4,181 (3,618-4,744)	5,118 (4,115-6,122)	1,009 (773-1,245)
Latvia	330 (288-371)	207 (182-232)	200 (175-224)	219 (180-258)	47 (39-55)
Lithuania	490 (432-548)	241 (206-276)	216 (182-250)	211 (153-269)	60 (48-73)
Luxembourg	97 (86-109)	47 (40-54)	44 (37-51)	78 (66-90)	13 (10-15)
Malta	57 (49-65)	33 (28-38)	35 (30-40)	51 (42-59)	12 (10-14)
Netherlands	1,925 (1,593-2,257)	793 (592-994)	643 (446-840)	597 (262-931)	462 (383-540)
Norway	765 (652-878)	506 (438-574)	438 (371-505)	838 (720-955)	61 (33-88)
Poland	7,120 (6,423-7,817)	3,587 (3,165-4,010)	3,047 (2,634-3,460)	4,596 (3,868-5,325)	936 (762-1,111)
Portugal	1,307 (1,150-1,463)	437 (342-532)	611 (519-704)	713 (548-879)	270 (228-312)
Romania	3,173 (2,808-3,537)	2,124 (1,903-2,345)	2,135 (1,919-2,351)	1,619 (1,259-1,978)	421 (337-505)
Slovakia	1,122 (1,017-1,228)	605 (541-669)	417 (355-480)	535 (427-643)	97 (71-122)
Slovenia	372 (332-413)	166 (142-190)	149 (125-173)	231 (190-273)	49 (39-58)
Spain	6,854 (6,043-7,664)	3,279 (2,788-3,770)	3,120 (2,640-3,600)	2,653 (1,808-3,498)	803 (598-1,008)
Sweden	1,602 (1,382-1,822)	1,015 (882-1,149)	1,123 (992-1,253)	1,300 (1,078-1,523)	335 (284-386)
United Kingdom	13,127 (9,917-16,337)	8,191 (6,400-9,982)	7,832 (6,123-9,541)	9,459 (6,672-12,246)	2,283 (1,748-2,817)

<sup>a</sup> RSV-associated hospitalisations in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisations in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 10: RSV-associated hospitalisations per age group per year calculated by using the nearest neighbor matching approach plus the first set of indicators

<b>Country</b>	<b>0-2 months (95%CI)<sup>a</sup></b>	<b>3-5 months (95%CI)<sup>a</sup></b>	<b>6-11 months (95%CI)<sup>a</sup></b>	<b>12-35 months (95%CI)<sup>b</sup></b>	<b>36-59 months (95%CI)<sup>b</sup></b>
EU28 <sup>c</sup>	90,595 (84,923-96,267)	49,002 (46,113-51,892)	43,851 (40,628-47,074)	51,303 (46,233-56,373)	10,657 (9,665-11,650)
Austria	1,241 (1,035-1,446)	685 (588-782)	624 (506-742)	878 (701-1,055)	153 (119-186)
Belgium	1,910 (1,593-2,226)	1,024 (873-1,175)	923 (742-1,105)	1,293 (1,033-1,553)	306 (254-357)
Bulgaria	1,228 (1,058-1,399)	668 (587-750)	569 (471-666)	599 (460-738)	121 (93-149)
Croatia	772 (672-872)	418 (371-466)	381 (324-439)	398 (309-487)	77 (60-95)
Cyprus	178 (155-201)	96 (85-107)	87 (73-100)	104 (83-125)	17 (13-21)
Czech Republic	2,179 (1,900-2,458)	1,157 (1,024-1,289)	990 (830-1,150)	1,215 (986-1,444)	257 (210-304)
Denmark	845 (695-995)	573 (502-644)	568 (482-654)	852 (726-978)	200 (174-225)
Estonia	260 (224-295)	144 (127-161)	134 (113-154)	162 (132-192)	36 (30-42)
Finland	1,101 (950-1,252)	611 (539-683)	479 (392-565)	637 (507-767)	103 (78-129)
France	17,120 (15,237-19,003)	8,642 (7,748-9,535)	8,995 (7,912-10,077)	8,939 (7,295-10,582)	1,708 (1,387-2,028)
Germany	12,374 (10,547-14,201)	6,518 (5,652-7,385)	5,722 (4,672-6,773)	7,425 (5,913-8,938)	1,290 (1,008-1,572)
Greece	1,646 (1,413-1,878)	860 (749-970)	754 (621-887)	717 (507-927)	195 (151-238)
Hungary	1,661 (1,426-1,897)	927 (815-1,039)	844 (709-979)	932 (735-1,128)	201 (165-238)
Ireland	1,278 (1,113-1,442)	700 (622-779)	661 (566-755)	742 (596-889)	141 (112-169)

Italy	10,217 (8,948-11,486)	5,205 (4,601-5,809)	4,462 (3,736-5,188)	4,381 (3,245-5,517)	1,007 (783-1,230)
Latvia	435 (380-490)	234 (208-260)	211 (179-242)	203 (160-246)	38 (30-45)
Lithuania	565 (488-642)	317 (281-354)	275 (231-319)	311 (245-376)	60 (48-72)
Luxembourg	97 (82-112)	52 (44-59)	44 (35-53)	60 (46-74)	10 (8-13)
Malta	81 (70-93)	43 (38-49)	39 (32-45)	42 (32-52)	9 (7-11)
Netherlands	2,110 (1,653-2,568)	909 (691-1,126)	825 (564-1,087)	810 (445-1,176)	435 (360-509)
Norway	845 (687-1,003)	525 (451-599)	476 (386-566)	810 (675-946)	71 (45-98)
Poland	6,420 (5,490-7,351)	3,473 (3,030-3,916)	2,930 (2,397-3,463)	3,360 (2,536-4,185)	787 (625-949)
Portugal	1,591 (1,383-1,800)	845 (745-944)	716 (596-835)	819 (631-1,006)	186 (147-226)
Romania	3,206 (2,719-3,693)	1,652 (1,420-1,884)	1,402 (1,123-1,680)	1,423 (1,017-1,830)	412 (332-492)
Slovakia	1,044 (907-1,182)	574 (509-640)	520 (441-599)	587 (465-710)	103 (78-127)
Slovenia	418 (364-471)	228 (202-253)	195 (164-225)	228 (182-273)	46 (37-55)
Spain	7,960 (6,877-9,042)	3,934 (3,419-4,450)	3,660 (3,040-4,279)	2,838 (1,914-3,761)	833 (639-1,028)
Sweden	1,810 (1,506-2,113)	1,038 (893-1,182)	973 (800-1,147)	1,340 (1,088-1,593)	294 (246-342)
United Kingdom	12,103 (9,301-14,904)	7,139 (5,745-8,533)	6,816 (5,258-8,375)	10,200 (7,778-12,623)	2,433 (1,955-2,911)

<sup>a</sup> RSV-associated hospitalisations in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisations in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 11: RSV-associated hospitalisations per age group per year calculated by using the nearest neighbor matching approach plus the second set of indicators

<b>Country</b>	<b>0-2 months (95%CI)<sup>a</sup></b>	<b>3-5 months (95%CI)<sup>a</sup></b>	<b>6-11 months (95%CI)<sup>a</sup></b>	<b>12-35 months (95%CI)<sup>b</sup></b>	<b>36-59 months (95%CI)<sup>b</sup></b>
EU28 <sup>c</sup>	92,625 (86,477-98,773)	49,479 (46,343-52,615)	46,170 (42,524-49,815)	42,482 (37,614-47,350)	9,393 (8,547-10,239)
Austria	1,294 (1,071-1,518)	635 (531-738)	567 (440-693)	564 (390-738)	138 (108-167)
Belgium	2,088 (1,742-2,434)	994 (833-1,155)	952 (755-1,148)	977 (704-1,251)	279 (231-327)
Bulgaria	1,314 (1,127-1,500)	714 (627-800)	659 (553-765)	499 (358-640)	109 (84-135)
Croatia	749 (639-858)	400 (349-451)	378 (316-440)	302 (215-390)	69 (54-85)
Cyprus	177 (151-202)	94 (82-106)	87 (72-101)	81 (61-102)	16 (12-19)
Czech Republic	2,147 (1,842-2,451)	1,168 (1,026-1,310)	1,099 (926-1,272)	892 (659-1,125)	203 (161-245)
Denmark	876 (717-1,034)	579 (505-653)	584 (494-674)	810 (686-934)	189 (166-211)
Estonia	260 (222-297)	142 (124-160)	130 (109-152)	115 (85-145)	27 (22-33)
Finland	1,125 (965-1,285)	617 (543-691)	491 (401-582)	590 (463-718)	93 (71-116)
France	17,930 (15,882-19,977)	8,929 (7,976-9,882)	9,479 (8,317-10,640)	6,938 (5,322-8,554)	1,560 (1,274-1,846)
Germany	12,660 (10,674-14,646)	6,368 (5,443-7,293)	5,777 (4,650-6,904)	5,923 (4,437-7,410)	1,307 (1,056-1,558)
Greece	1,751 (1,496-2,005)	936 (818-1,055)	893 (749-1,037)	602 (395-808)	175 (136-214)
Hungary	1,868 (1,611-2,126)	1,004 (884-1,123)	964 (818-1,110)	775 (582-968)	155 (122-187)
Ireland	1,323 (1,143-1,504)	709 (625-792)	693 (590-795)	682 (538-826)	129 (103-154)

Italy	9,927 (8,541-11,314)	5,254 (4,609-5,900)	4,843 (4,056-5,629)	3,599 (2,482-4,716)	1,062 (863-1,262)
Latvia	434 (373-494)	232 (204-260)	219 (185-253)	182 (138-226)	35 (28-42)
Lithuania	565 (481-649)	320 (281-359)	302 (254-350)	268 (204-333)	56 (46-67)
Luxembourg	100 (83-116)	53 (45-61)	48 (38-58)	54 (40-67)	10 (7-12)
Malta	81 (69-94)	44 (38-49)	40 (33-47)	39 (29-49)	8 (6-10)
Netherlands	2,218 (1,733-2,702)	921 (696-1,147)	843 (569-1,118)	637 (265-1,009)	324 (257-390)
Norway	843 (665-1,021)	515 (434-597)	466 (365-566)	755 (617-892)	61 (37-85)
Poland	6,750 (5,733-7,766)	3,687 (3,214-4,161)	3,468 (2,891-4,044)	2,954 (2,143-3,764)	669 (521-817)
Portugal	1,546 (1,318-1,774)	812 (705-918)	691 (561-820)	687 (503-871)	164 (129-200)
Romania	3,379 (2,847-3,911)	1,762 (1,515-2,010)	1,685 (1,383-1,987)	1,115 (715-1,515)	331 (260-402)
Slovakia	1,022 (868-1,176)	558 (487-630)	525 (438-612)	431 (311-551)	104 (83-126)
Slovenia	444 (385-503)	233 (206-260)	206 (173-240)	166 (120-213)	38 (30-46)
Spain	7,730 (6,548-8,912)	4,049 (3,498-4,599)	3,916 (3,245-4,586)	2,595 (1,655-3,535)	755 (582-929)
Sweden	1,874 (1,553-2,196)	1,044 (895-1,194)	979 (797-1,161)	1,180 (932-1,428)	224 (180-267)
United Kingdom	12,289 (9,332-15,246)	7,479 (5,992-8,965)	7,465 (5,744-9,185)	9,672 (7,175-12,168)	2,025 (1,585-2,466)

<sup>a</sup> RSV-associated hospitalisations in these three age groups are estimated by also including data from France reported by Demont and colleagues [Demont, 2020]

<sup>b</sup> RSV-associated hospitalisations in these two age groups are estimated by also including data from Spain reported by Gil-Prieto and colleagues [Gil Prieto, 2015]

<sup>c</sup> Includes the UK and excludes Norway

Supplementary File 12: Description of individual studies included in the analysis\*

<b>References</b>	<b>Country/countries analyzed</b>	<b>Study Period</b>	<b>Quality assessment score</b>
<b>Johannesen et al. 2022</b>	Denmark, England, Finland, Netherlands, Norway, Scotland	2010-2016	0.8
<b>Demont et al. 2020</b>	France	2010-2018	0.7
<b>Gil-Prieto et al. 2015</b>	Spain	1997-2011	0.7

\* The paper by Johannesen et al. was here reported and analyzed from completeness, even if it did not result from the systematic review of the literature



Supplementary File 13: PRISMA 2020 Main Checklist

Topic	No.	Item	Location where item is reported
<b>TITLE</b>			
<b>Title</b>	1	Identify the report as a systematic review.	1
<b>ABSTRACT</b>			
<b>Abstract</b>	2	See the PRISMA 2020 for Abstracts checklist	
<b>INTRODUCTION</b>			
<b>Rationale</b>	3	Describe the rationale for the review in the context of existing knowledge.	4
<b>Objectives</b>	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	4
<b>METHODS</b>			
<b>Eligibility criteria</b>	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5-6
<b>Information sources</b>	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	6
<b>Search strategy</b>	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	6
<b>Selection process</b>	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	6
<b>Data collection process</b>	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	6
<b>Data items</b>	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	6-7

Topic	No.	Item	Location where item is reported
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	6-7
<b>Study risk of bias assessment</b>	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	7, Supplementary File 2
<b>Effect measures</b>	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	N/A
<b>Synthesis methods</b>	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item 5)).	6
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	N/A
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	N/A
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	N/A
<b>Reporting bias assessment</b>	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	N/A
<b>Certainty assessment</b>	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	N/A
<b>RESULTS</b>			

Topic	No.	Item	Location where item is reported
<b>Study selection</b>	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	8-9
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	8-9
<b>Study characteristics</b>	17	Cite each included study and present its characteristics.	9
<b>Risk of bias in studies</b>	18	Present assessments of risk of bias for each included study.	14, Supplementary File 12
<b>Results of individual studies</b>	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	9
<b>Results of syntheses</b>	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	N/A
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	N/A
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	N/A
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	N/A
<b>Reporting biases</b>	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	N/A
<b>Certainty of evidence</b>	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	N/A
<b>DISCUSSION</b>			
<b>Discussion</b>	23a	Provide a general interpretation of the results in the context of other evidence.	12-13
	23b	Discuss any limitations of the evidence included in the review.	13-14
	23c	Discuss any limitations of the review processes used.	N/A

Topic	No. Item	Location where item is reported
	23d Discuss implications of the results for practice, policy, and future research.	14-15
<b>OTHER INFORMATION</b>		
<b>Registration and protocol</b>	24a Provide registration information for the review, including register name and registration number, or state that the review was not registered.	N/A
	24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	N/A
	24c Describe and explain any amendments to information provided at registration or in the protocol.	N/A
<b>Support</b>	25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	16
<b>Competing interests</b>	26 Declare any competing interests of review authors.	16
<b>Availability of data, code and other materials</b>	27 Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	N/A

Supplementary File 14: PRIMSA Abstract Checklist

Topic	No.	Item	Reported?
<b>TITLE</b>			
<b>Title</b>	1	Identify the report as a systematic review.	Yes
<b>BACKGROUND</b>			
<b>Objectives</b>	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
<b>METHODS</b>			
<b>Eligibility criteria</b>	3	Specify the inclusion and exclusion criteria for the review.	Yes
<b>Information sources</b>	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	No
<b>Risk of bias</b>	5	Specify the methods used to assess risk of bias in the included studies.	No
<b>Synthesis of results</b>	6	Specify the methods used to present and synthesize results.	Yes
<b>RESULTS</b>			
<b>Included studies</b>	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
<b>Synthesis of results</b>	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
<b>DISCUSSION</b>			
<b>Limitations of evidence</b>	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	No
<b>Interpretation</b>	10	Provide a general interpretation of the results and important implications.	Yes
<b>OTHER</b>			
<b>Funding</b>	11	Specify the primary source of funding for the review.	No
<b>Registration</b>	12	Provide the register name and registration number.	No

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv.

2020, September 14. DOI: 10.31222/osf.io/v7gm2. For more information, visit:  
[www.prisma-statement.org](http://www.prisma-statement.org)